Pricing Log in Create free account
Saturday 17 October 2026 Export QURE’s income statement to Excel — free account

uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 22.08
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 2 — 2 2 8 — 1 18 1 — — —
Insider Ownership 2.69%

Capital & Financial Ratios $m

Market Cap 1,560.00
Revenue 18.67
Net Income (252.21)
Free Cash Flow (161.45)
Net Debt (760.19)
Current Ratio 10.01 (at or above 1.5: strong)
Debt/Equity 0.15 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (7.70) (negative: loss-making)
P/S ratio 77.06 (above 10: high)
P/B ratio 4.44
Past 5Y EPS Growth —
This Y EPS Growth (12.03%) (below 0%: weak)
Next Y EPS Growth 22.13% (at or above 15%: strong)
Next Y revenue growth 48.53% (at or above 10%: strong)
Next 5Y EPS Growth 30.27% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 36.8×, against a ten-year median of 16.1×; over the ten years it ranged from −16.4× in 2024 to 428× in 2020.
P/S against its own 10 years 68.12%
10-year low 10-year high
P/B against its own 10 years 46.70%
10-year low 10-year high
EV/Sales against its own 10 years 57.06%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 618 368 623 810
Receivables 4 6 6 6
Inventory 12 — — —
Other 3 8 7 8
652 390 656 834
2023 2024 2025 Q'26
Payables 7 7 5 5
ST’ Debt — — — —
Other 28 — 13 24
74 40 63 83

Compound Annual Growth %

10y 5y 3y
Sales 4.29% (15.57%) (46.73%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 4.51% (4.00%) (25.24%)

Revenue $m

Mar Jun Sep Dec Year
’26 4 6 — — —
’25 2 5 4 6 16
’24 8 11 2 5 27
’23 5 2 1 7 16
’22 2 0 1 103 106
’21 0 464 2 58 524
’20 0 2 2 34 38
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (38) (29) — — —
’25 (44) (40) (16) (78) (178)
’24 (61) (33) (37) (53) (183)
’23 (78) (57) 39 (50) (146)
’22 (26) (16) (49) (55) (145)
’21 (41) 416 (40) (47) 288
’20 (33) (30) (35) (37) (135)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (38) (29) — — —
’25 (44) (40) (16) (78) (178)
’24 (63) (33) (37) (53) (186)
’23 (81) (58) 37 (52) (153)
’22 (30) (20) (53) (60) (163)
’21 (45) 414 (48) (51) 271
’20 (36) (32) (37) (40) (144)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.85) (1.22) — — —
’25 (0.82) (0.69) (1.38) (0.56) (3.46)
’24 (1.36) (1.16) (0.91) (1.50) (4.92)
’23 (1.63) (1.44) (1.88) (1.53) (6.47)
’22 (1.00) (0.84) (1.02) 0.15 (2.71)
’21 (0.91) 8.51 (0.79) 0.17 7.04
’20 (0.63) (0.96) (1.21) (0.01) (2.81)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 5.45 4.72 16.77 26.94 34.38 19.50 12.52 5.49 3.73 7.76

Analyst estimates 2026–2028

Powerpack
High 19.40 21.35 43.23 82.49 76.69 42.27 28.26 23.46 18.42 71.50
People
People Employees 251 202 212 248 332 463 501 480 209 221
Revenue/emp, $m 0.10 0.06 0.05 0.03 0.11 1.13 0.21 0.03 0.13 0.07
Income, $m
Income, $m Revenue 25 13 11 7 38 524 106 16 27 16
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 96.86 13.98 32.42 89.53
EBT (72) (79) (83) (124) (141) 333 (128) (307) (237) (193)
EBT margin, % (287.79) (606.23) (736.20) (1,705.82) (377.04) 63.51 (120.45) (1,934.97) (874.39) (1,201.02)
Net income (73) (79) (83) (124) (125) 330 (127) (308) (240) (199)
Depreciation 6 8 12 7 11 7 9 12 13 15
Per share, $
Per share, $ Revenue 1.00 0.49 0.32 0.18 0.84 11.39 2.28 0.33 0.56 0.28
Earnings (2.93) (2.94) (2.34) (3.11) (2.81) 7.17 (2.71) (6.47) (4.92) (3.46)
Cash flow (2.88) (2.38) (2.13) (2.47) (3.03) 6.26 (3.10) (3.06) (3.76) (3.09)
Capex (0.69) (0.21) (0.12) (0.17) (0.21) (0.38) (0.38) (0.15) (0.07) (0.01)
Free cash flow (3.57) (2.59) (2.25) (2.63) (3.25) 5.88 (3.48) (3.21) (3.83) (3.10)
Book value 2.54 3.31 5.04 8.08 5.49 12.96 10.19 4.36 (0.14) 3.46
Shares, m 25 27 36 40 44 46 47 48 49 58
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 2.90 0.00 0.00 0.00 0.00
P/S 5.86 41.50 91.03 393.68 42.83 1.82 9.59 20.85 31.68 85.48
P/B 2.31 6.09 5.72 8.87 6.59 1.60 2.14 1.59 0.00 6.92
EV/Sales 1.38 30.93 74.08 347.87 37.47 0.97 7.31 (11.21) 20.32 50.40
EV/FCF (0.39) (5.80) (10.41) (24.05) (9.74) 1.89 (4.72) 1.14 (2.93) (4.49)
Cash, $m
Cash, $m Operating cash flow (72) (64) (76) (99) (135) 288 (145) (146) (183) (178)
Capex (17) (6) (4) (7) (9) (17) (18) (7) (3) 0
Free cash flow (89) (70) (80) (105) (144) 271 (163) (153) (186) (178)
Balance, $m
Balance, $m Working capital 121 144 217 353 232 591 401 578 350 593
Total debt 20 21 44 36 36 101 103 102 51 50
Net debt (112) (139) (191) (342) (209) (455) (250) (516) (316) (573)
Shareholders’ equity 64 89 180 323 244 596 476 208 (7) 199
Returns, %
Returns, % ROA (32.40) (39.64) (34.46) (34.38) (31.69) 57.34 (16.75) (40.15) (34.51) (28.81)
ROIC 0.00 0.00 0.00 0.00 (226.63) 138.19 (39.60) 0.00 0.00 0.00
ROE (76.61) (103.61) (61.94) (49.42) (44.10) 78.50 (23.66) (90.24) (238.46) (207.10)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

uniQure N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OCUL Ocular Therapeutix, Inc. $1.6B — (loss-making) — (loss-making) +0.12% (above 0%: growing) n/m −25.35% (below 0%: shrinking) 85.08% (609.34%) Compare
NTLA Intellia Therapeutics, Inc. $1.6B — (loss-making) — (loss-making) −46.23% (below 0%: shrinking) n/m +15.05% (above 0%: growing) 100.00% (1,472.25%) Compare
STOK Stoke Therapeutics, Inc. $1.6B — (loss-making) — (loss-making) −32.51% (below 0%: shrinking) n/m −128.97% (below 0%: shrinking) 100.00% (701.65%) Compare
GPCR Structure Therapeutics Inc. Sponsored ADR $1.6B — (loss-making) — — n/m −119.15% (below 0%: shrinking) 0.00% 0.00% Compare
QURE uniQure N.V. $1.6B — (loss-making) — (loss-making) +11.00% (above 0%: growing) n/m +27.66% (above 0%: growing) 94.01% (893.73%)
KRSA Korsana Biosciences, Inc. $1.5B — (loss-making) — (loss-making) −43.24% (below 0%: shrinking) n/m −184.69% (below 0%: shrinking) 100.00% 0.00% Compare
MAZE Maze Therapeutics, Inc. $1.5B — (loss-making) — — n/m +50.21% (above 0%: growing) 100.00% 0.00% Compare
ABSI Absci Corporation $1.5B — (loss-making) — (loss-making) −46.37% (below 0%: shrinking) n/m −71.74% (below 0%: shrinking) 100.00% (10,741.51%) Compare
IMCR Immunocore Holdings PLC Sponsored ADR $1.5B — (loss-making) 208× +18.34% (above 0%: growing) n/m −40.74% (below 0%: shrinking) 99.06% (2.58%) Compare
Median of peers $1.6B — — −37.88% — −56.24% 100.00% (305.96%)

All 614 Biotechnology stocks →

uniQure N.V. (QURE) key facts

  • Concern: uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024.
  • uniQure N.V. (QURE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, QURE traded at $21.72, a market capitalization of $1.6 billion.
  • Return on equity was −207.1% and debt-to-equity 0.15.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.80 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

uniQure N.V. (QURE) Latest News

2 Sep

Impact 5 ·

19 Jun

Impact 5 ·
Impact 5 ·

17 Jun

Impact 5 ·
Impact 5 ·
Impact 5 ·

5 Mar

Impact 5 ·

2 Mar

Impact 5 ·
Impact 5 ·

25 Sep

Impact 5 ·

24 Sep

Impact 5 ·
stockrow.com/QURE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com